Targeting tumour hypoxia: shifting focus from oxygen supply to demand.
Br J Radiol
; 92(1093): 20170843, 2019 Jan.
Article
em En
| MEDLINE
| ID: mdl-29436847
ABSTRACT
Tumour hypoxia is a well-recognised barrier to anti-cancer therapy and represents one of the best validated targets in oncology. Previous attempts to tackle hypoxia have focussed primarily on increasing tumour oxygen supply; however, clinical studies using this approach have yielded only modest clinical benefit, with often significant toxicity and practical limitations. Therefore, there are currently no anti-hypoxia treatments in widespread clinical use. As an emerging alternative strategy, we discuss the relevance of inhibiting tumour oxygen metabolism to alleviate hypoxia and highlight recently initiated clinical trials using this approach.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carga Tumoral
/
Hipóxia Tumoral
/
Nimorazol
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article